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Abstract 
Radiopharmaceuticals have proven to be effective agents, since they can be successfully applied for both diagnostics 
and therapy. Effective application of relevant radionuclides in pre-clinical and clinical studies depends on the choice 
of a sufficient delivery platform. Herein, we provide a comprehensive review on the most relevant aspects in radionu-
clide delivery using the most employed carrier systems, including, (i) monoclonal antibodies and their fragments, (ii) 
organic and (iii) inorganic nanoparticles, and (iv) microspheres. This review offers an extensive analysis of radionuclide 
delivery systems, the approaches of their modification and radiolabeling strategies with the further prospects of their 
implementation in multimodal imaging and disease curing. Finally, the comparative outlook on the carriers and radio-
nuclide choice, as well as on the targeting efficiency of the developed systems is discussed.
Keywords: Nuclear medicine, Diagnostic and therapeutic radionuclides, Drug carrier systems, Monoclonal 
antibodies, Nanoparticles, Microspheres, Radiopharmaceuticals, Theranostics, Multimodal imaging
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Since the discovery of radioactivity by Henri Becquerel 
and Marie Curie, and first medical application of radium 
by Henri Alexandre Danlos and Eugene Bloch for the 
treatment of tuberculous skin lesion, the radionuclide 
therapy has made significant progress. Nowadays, it is 
hard to overestimate the importance of radionuclides 
application in medicine, as they are extensively used in 
both diagnostics and therapy [1]. The reason for such 
demand is explained by two main factors. First of all, the 
radionuclides are highly effective and universal cytotoxic 
agents that are capable of destroying cells with ionizing 
radiation, which cannot be avoided or negated by any 
cellular means [2]. Secondly, the use of γ and β+ emit-
ters is crucial for diagnostics, because it allows one to 
take advantage of superior imaging methods utilizing 
the emission for precise detection of the radionuclide 
distribution in the whole organism. Although radionu-
clides possess unique diagnostic and therapeutic fea-
tures, they are not able to selectively target tumor sites 
(with only few exceptions, e.g. 131I can passively accu-
mulate at the tumor tissues, expressing sodium/iodide 
symporter (NIS) [3–5]), thus, issues related to the radio-
nuclide delivery become an area of a significant interest 
and growth.
As a matter of fact, drug delivery systems promote the 
concentration of the drug reaching the target site and the 
enhanced pharmacokinetic profiles [6]. The addressable 
delivery of the drug can usually occur via active or passive 
targeting. The passive targeting is performed via accu-
mulation of drug carriers at a particular site due to the 
inherent pathophysiological, physicochemical or phar-
macological factors [7–9]. While the active targeting is 
occurred when the drug carriers are modified with active 
targeting ligands, possessing a high affinity for binding to 
a specific cell type or tissue in the organism [10–12]. In 
contrast to the off-target drug delivery, the active target-
ing enables enhanced therapeutic efficiency and reduced 
side effects associated with the systemic toxicity [13]. The 
same principles are true when it comes to the delivery 
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of radionuclides. The use of delivery systems, which can 
ensure the addressable delivery of the loaded cargo, is 
crucial for both therapeutic and diagnostic radionuclides. 
The more effective delivery of radionuclides will ensure a 
lowering in demand of these agents, which allow decreas-
ing isotope dose administrated per patient to reduce a 
risk of exposure and costs [14–16]. Also, selective target-
ing of diagnostic radionuclides at the site of interest will 
provide increasing image quality when positron emission 
tomography (PET) or single-photon emission computed 
tomography (SPECT) is performed. The targeting deliv-
ery of radionuclides becomes the main priority since the 
high amounts of irradiation during the treatment in unfa-
vorable delivery areas can result in possible side effects. 
Additionally, delivery systems can be modified to provide 
further possibilities of detection and visualization. Such 
augmentation can further enhance the diagnostic value 
of radiopharmaceuticals and is important for the deliv-
ered dose estimation when it comes to the therapeutic 
radionuclides. The concept of active targeting delivery of 
radionuclides is presented in Fig. 1.
The application of radionuclide is determined by its 
nature. Radioisotopes commonly used for the therapeu-
tic radiopharmaceuticals emit α-, β-particles, or Auger 
electrons, which cause cytotoxic deoxyribonucleic acids 
(DNA) damage through numerous mechanisms such 
as reactive oxygen species, single and double stranded 
breaks, and inhibition of DNA repair mechanisms [17, 
18]. The emissions of β-, α-, and Auger particles vary 
in penetrating range (Fig. 2) and linear energy transfer 
(LET), thus the choice of radionuclide depends on mul-
tiple factors, such as the type and size of the targeted 
cancer, density of the target and its heterogeneity.
The β− emitters have a low LET (0.2 keV/mm) and a 
relatively long penetrating range in tissue (one to sev-
eral mm), as a result, they can penetrate deep in the 
tumor and can also partially damage the surrounding 
normal tissues. Common β− emitters include 177Lu, 90Y 
and 131I, which has already been used for thyroid cancer 
treatment. Both iodine and lutetium radioisotopes co-
emit a γ photon that can be detected by SPECT [19].
The radionuclides with β+ decay emit positron and 
are used exclusively for diagnostical purposes and can 
be visualized via PET. Commonly used β+ emitters are 
usually short-lived (e.g.15O, 13N, 11C and 18F) and used 
to estimate the location of disease and quantitatively 
examine various biochemical and physiological pro-
cesses. However, the interest in the application of the 
long lived β+ emitters (89Zr, 64Cu and 52Mn) has arisen, 
since they can be used to monitor the course of treat-
















Fig. 1 Administration of radionuclide carriers in the tumor site and their further accumulation via active targeting approach
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The emitted α-particles can penetrate only a few cell 
diameters (50–100 µm in soft tissue) and have a high LET 
(80–100  keV/µm); therefore, they can be more effective 
for treatment of smaller lesions and metastases. Com-
monly used α-emitters include 213Bi, 223Ra, radiohalogen 
211At, radiometal 225Ac [21]. One of the most frequently 
used in nuclear medicine radioisotopes is 225Ac, which 
consecutively undergoes four α-decays, during two of 
which γ ray is emitted. This isotope has been success-
fully applied for tumor therapy in preclinical and clini-
cal studies [22–24]. Auger emitters (125I and 99mTc) have 
high LET (4–26  keV/µm) with a very short penetration 
depth of 2 to 500 nm [25]. Therefore, Auger emitters like 
α-emitters are more suitable for minimizing damage of 
the normal tissues compared to β-emitters [26]. How-
ever, due to the small penetration depth of Auger elec-
trons, the radionuclides should be delivered at the closest 
proximity to the cell. For this reason, the development of 
the radionuclide delivery systems is required.
This review is focused on known radionuclide delivery 
systems traditionally applied in nuclear medicine, which 
are categorized into four main groups: (i) antibodies and 
Fig. 2 Types of radioactive decay with the demonstration of the soft tissue penetration range
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antibody fragments, (ii) organic and (iii) inorganic nano-
particles (NPs), and finally (iv) microspheres (Fig. 1). We 
describe the design considerations of recently developed 
radionuclide delivery systems, their modifications and 
radiolabeling approaches, as well as a current state in 
clinical and preclinical studies, or their potential to be 
implemented into the clinical practice.
Antibodies and antibody fragments
Immunoglobulin type G (IgG) monoclonal antibod-
ies (mAbs) are the most commonly used type of target-
ing molecules for pharmaceutical application, including 
radiomedicine. Their size is approximately 150 kDa, and 
mAbs are composed of two identical polypeptide “heavy 
chains” paired with two “light chains”. MAbs consist of 
an antigen-binding fragment (Fab), a fragment crystalliz-
able (Fc), two disulfide bonds in the hinge region and a 
conserved glycosylation site at amino acid N297 of each 
heavy chain (Fig. 3) [27]. MAbs can specifically bind anti-
gens without further modifications, and thus they already 
possess targeting properties.
The mAbs labeled with a γ- or positron-emitting radio-
nuclide are actively used for quantitative biodistribution 
imaging using SPECT or PET [28]. The use of mAbs-
based PET and SPECT has been implemented in cancer 
treatment to guide therapy selection, to estimate dosime-
try for radioimmunotherapy (RIT), and to track response 
to therapy [29, 30]. Apart from imaging of oncological 
targets, immunoPET has been employed for detection 
and tracking of immune cells [31]. The immunoPET 
can also be used to monitor inflammation and immune 
responses [32].
Given the nature of attached radionuclide, the same 
antibody can be used for both diagnostic imaging and 
RIT, thus, providing a theranostic platform [33]. A num-
ber of works showed efficiency of RIT [34–36] in hemat-
opoietic cancers and to a lesser extent, solid tumors [37].
Additionally, there is an approach in radiomedicine in 
which theranostic radionuclide pairs such as 86Y and 90Y 
are used [38, 39]. For instance, mAbs labeled with diag-
nostic radionuclides (β+ emitter 86Y) were administered 
first in order to localize the tumor site and determine the 
specificity of the applied mAbs. Since the 86Y and 90Y are 
the same element, the distribution and pharmacokinet-
ics of mAbs labeled with these radionuclides is the same. 
This allows a very precise estimation of the required 
dosage of therapeutic radionuclide for RIT and, thus, 
improvement of the treatment [38, 39].
Nonetheless, mAbs possess certain disadvantages, 
which are common to any therapeutic radionuclide car-
riers. For example, a decay is a continuous process, which 
occurs without any regard to whether the mAbs are 
bonded to their antigens or not. Therefore, it is important 
to shorten the free circulation period of the radioconju-
gates as much as possible. MAbs themselves typically 
exhibit long circulation times in blood (which contributes 
to bone marrow toxicity) and a reduced diffusion into 
the tumoral mass, which can lead to the accumulation of 
radionuclides in critical organs, especially, in liver. There 
are some possibilities to address it such as the optimiza-
tion of antibody pharmacokinetics, biodistribution, and 
clearance in vivo. At the present moment, antibody-based 
delivery optimization can be achieved using modern pro-
tein engineering, which allows to reformate intact mAbs 
into smaller derivatives of antibodies. These derivatives 
include smaller monovalent fragments such as single 
domain antibodies (sdAbs), diabodies, minibodies, pro-
tein scaffolds, and more complex bispecific antibodies 
(bsAbs). Their structures are represented in Fig.  3. The 
smaller antibody fragments are able to clear more rapidly 
from the circulation compared to the intact mAbs, result-
ing in better contrast images after shorter periods of time. 
For imaging, antibody fragments that lack the Fc region 
are desired due to the removal of the biological function 
and neonatal Fc receptor (FcRn) recycling, which allows 
to obtain the optimal contrast at shorter time periods. 
Wu et  al. have shown that the reduction of the molecu-
lar weight of antibodies below ~ 60 kDa can dramatically 
accelerate clearance. For example, high contrast images 
can be obtained for small single‐domain antibodies or 
diabodies within the same day (4–8 h), compared to the 
larger minibodies, which are usually formed by the next 
day (24–48  h) [29]. Thus, smaller antibodies offer cer-
tain advantages regarding better pharmacokinetics. For 
therapeutic applications, the circulation time of the radi-
olabeled antibody fragments, on one hand, needs to be 
sufficient for the dose deposition in tumors, while limit-
ing toxicity to normal tissues. The plasma half‐life of small 
fragments and scaffolds (targeting molecules of protein 
nature [40]) can be extended by chemical or recombinant 
approaches such as poly(ethylene glycol) (PEG) modifi-
cation (PEGylation) or fusion to Fc domain, albumin, or 
albumin‐binding proteins. The influence of antibody vari-
ations created by joining antibody variable light  (VL) and 
variable heavy  (VH) domains on their plasma half-lives 
detected by PET is presented in Fig. 3. The tumor penetra-
tion and renal uptake is increased with the size reduction 
of antibodies. However, the smaller antibody fragments 
for RIT have a lower size than renal filtration cutoff and, 
therefore, they are cleared through the kidneys, which is 
less radioresistant compared to liver.
Minibodies
The minibody is a bivalent dimer comprising of a single-
chain variable fragments (scFv) with a human IgG con-
stant heavy chain 3 domain (Fig. 3) with a serum half-life 
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of 5–12 h, and due to its size (~ 80 kDa) is excreted via 
hepatic clearance [41]. Radiolabeled minibodies were 
used as diagnostic PET imaging tracers targeting 
carcinoembryonic antigen (CEA) [42, 43], CD8 T cells 
[44], CD20 B Cells, PSCA and prostate-specific mem-















































































Fig. 3 a Correlation between blood clearance, tumor penetration, plasma half-life and renal uptake and the previously discussed antibodies and 
antibody fragments of different size: bsAbs, intact MAbs, scFv, sdAbs and alternative protein scaffolds. Uptake is expressed as percentage of injected 
dose per gram (ID/g). b PET/computed tomography (CT) images of mice bearing prostate stem-cell antigen (PSCA)–expressing LAPC-9 prostate 
cancer xenografts. PSCA expression was visualized with intact mAbs, single-chain Fv–Fc (scFV-Fc) wild type (WT) mAbs, scFV-Fc double mutant 
(DM) mAbs, Minibodies and Diabody labeled with N-succinimidyl-4-[18F]-fluorobenzoate (18F-SFB). All microPET images were scaled individually to 
best show tumor targeting (this figure was reproduced from Scott et al. [29] with the required copyright permission)
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Minibody, composed of the recombinant scFv of 
L19 antibody and the constant heavy chain 4 domain 
of human IgE (L19-SIP), was engineered to target extra 
domain B of fibronectin. 131I-L19-SIP demonstrated 
superior therapeutic efficacy compared with dimeric scFv 
or mAbs in teratocarcinoma tumor-bearing mice [32].
For imaging, 124I-L19-SIP (radretumab) was developed 
as an immunoPET tracer to perform patient selection in 
clinical trials, which later received 131I-L19-SIP RIT. Thus, 
124I-L19-SIP was used to predict dosage delivered to 
tumors in patients with brain metastases, while 131I-L19-
SIP was tested as RIT in combination with external beam 
radiation in patients with multiple brain metastases. 
The results showed reduction in 18F-fluorodeoxyglucose 
(FDG) uptake in common patients. Radretumab was 
also tested in patients with relapsed hematological can-
cers, where its diagnostic dose was preliminary used to 
determine eligibility for further treatment. In cases when 
tumor uptake was sufficient, three of ten patients who 
received radretumab showed complete response (clinical 
trial NCT01125085). Thus, patients with advanced lym-
phomas could benefit from concurrent chemotherapy.
Diabodies
The diabody is a noncovalent scFv dimer (~ 55  kDa) in 
which a shortened linker prevents the  VH and  VL from 
self-pairing, forcing cross-pairs in trans with a second 
chain to form a dimer, reconstituting two binding sites 
(Fig. 3). Radiolabeled diabodies are widely used for high-
contrast PET imaging of a variety of targets due to the 
improved tumor penetration compared to intact mAbs. 
The fast clearance of the diabodies with a plasma half-life 
of 2–5 h is advantageous for the same-day PET imaging 
of immune cell subsets, such as CD20, CD4 and CD8 T 
cells [46, 47], as well as solid tumors, including prostate 
cancer [48].
Single‑domain antibodies
Single-domain antibodies (sdAbs, 12–15  kDa) (Fig.  3) 
include small monomeric fragments derived from human 
 VH or  VL domains, linked with short peptide sequence, 
and has been given the commercial name Nanobody™ 
[49, 50]. These sdAbs have high stability, low immuno-
genicity and more compact structure for better targeting 
compared to IgG [51].
The camelid and shark domains have long comple-
mentarity-determining region 3 (CDR3), which allow for 
improved extension into cavities of target antigens [52]. 
More recent radiolabeled sdAbs studies have focused on 
the camelid VHH (Nanobody, registered trademark of 
“Ablynx NV”), and common targets include PSMA [53], 
CEA [54], and epidermal growth factor receptor (EGFR) 
[55], human epidermal growth factor receptor 2 (HER2) 
[56], and immune cell markers [57].
There are some nanobodies labeled with therapeu-
tic radionuclides. For instance, the sdAbs commercially 
available as Nanobody 2Rs15d labeled with 177Lu via 
diethylenetriaminepentaacetic acid (DTPA) and target-
ing tumor biomarker HER2 was evaluated in theranostic 
studies. 177Lu-DTPA-2Rs15d was injected in mice bear-
ing luciferase expressing ovarian cancer cell line SKOV-3 
xenografts. By the day 125 tumor growth was halted, 5 of 
8 mice were completely tumor-free and 3 other mice had 
small, but unpalpable tumors [58].
Nanobodies are also employed for diagnostics. For 
instance, Xavier et  al. reported synthesis and preclini-
cal validation of a novel anti-HER2 tracer, 68Ga-NOTA-
2Rs15d, for immunoPET. The described agents were 
capable of highly specific accumulation in the tumor 
areas and reduced kidney retention compared to the pre-
viously reported Nanobodies [59]. This was achieved by 
the removal of histidine tag. Overall, the reported tracer 
proved to be safe in  vivo. Further, Keyaert et  al. per-
formed clinical trials employing reported immunotracer 
[60]. In this work, 20 female patients with HER2-positive 
primary or metastatic breast carcinoma were involved. 
The studies revealed no adverse effects of tracer admin-
istration and the radiolabeled Nanobody was able to 
accumulate at HER2 overexpressing tumor sites at much 
higher concentrations compared to the healthy surround-
ing tissues. Therefore, authors continued their work in a 
Phase II clinical trials.
Alternative non‑antibody protein scaffolds
Alternative protein scaffolds (targeting molecule of pro-
tein nature) are easy to produce in bacteria or yeast, and 
are typically stable in harsh labeling conditions such as 
high temperature. They range from 2 to 20  kDa, which 
enables tissue penetration to access binding sites easier 
than mAbs (Fig.  3). However, the small size also results 
in a fast renal filtration, and certain applications may 
require additional engineering or other modifications 
to increase the plasma half-life. This can be achieved by 
PEGylation, Fc fusion, albumin fusion, or use of albu-
min binding domains [61]. A widely explored scaffold 
for radionuclide delivery is the Affibody (Affibody AB™), 
small (6.5 kDa) scaffolds composed of alpha helices origi-
nally based on the Z domain of staphylococcal protein A 
[62]. Affibodies rapidly penetrate tumors for early high-
contrast images due to rapid extravasation and tumor 
penetration [63], and they are compatible with short-
lived radionuclides such as 68Ga and 18F for PET, or 111In 
for SPECT. Affibody-based imaging and therapy have 
been developed to target EGFR [64] and HER2 [65].
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RIT studies in HER2-expressing tumor models sup-
port the development of the HER2-binding Affibody 
 ZHER2:342 to treat trastuzumab-resistant HER2 posi-
tive tumors. Due to the small size, the  ZHER2:342 clears 
rapidly and biodistribution studies with residualizing 
radionuclides show high renal reabsorption. There-
fore, fusion to an albumin-binding domain was used to 
reduce renal toxicity and increase circulation for thera-
peutic radionuclides [66]. For example, 177Lu labeled 
 ZHER2:342 successfully targeted HER2 positive microx-
enografts as confirmed by gamma-camera imaging, and 
the treatment extended survival in mice with high and 
low HER2 expressing tumors, however, overall mortal-
ity was caused by bone marrow toxicity [67]. Another 
study describes biodistribution of anti-HER2 Affibody 
 ZHER2:395-TCO and residualizing radiometals 111In and 
177Lu [65].
Bispecific antibodies
Antibody engineering enables novel functionality such 
as bispecific binding. Antibodies which contain two dif-
ferent antigen-binding sites in one molecule are called 
bispecific [68]. BsAbs can target two or more antigens 
resulting in improved delivery to a tumor for better 
imaging or therapeutic outcome. Brinkmann et  al. have 
recently reviewed the development and clinical imple-
mentation of bsAbs [69, 70]. BsAbs can be particularly 
useful for radionuclide delivery as part of a pretargeting 
strategy. According to pretargeting approach, one arm of 
the bispecific targets the tumor, and the other arm rec-
ognizes a radiolabeled hapten (typically a small molecule 
or peptide for imaging or RIT). The bsAbs are adminis-
tered first and only after sufficient time, they accumulate 
at the tumor and clear from the circulation. Further, the 
radiolabeled hapten is injected, which rapidly binds to 
the already pre-localized bsAbs [71]. Another effective 
pretargeting strategy uses a trivalent bsAb with two tar-
get-specific Fabs and an anti-histamine-succinyl-glycine 
Fab, which are linked to each other via disulfide bonds. 
Example targets for bsAbs pretargeting include CD105 
and EGFR [72], CEA [73], trophoblast antigen 2 (TROP2) 
[74].
Example of bispecific antibodies usage for pretarget-
ing strategy was reported in the recent work of Heskamp 
et al. [75]. The authors demonstrated the usage of Tri-Fab 
antibody TF2 consisting of anti-CEA with variable frag-
ments against histaminesuccinyl-glycine (HSG), which 
allow pretargeting of radiolabeled hapten–peptide IMP-
288. TF2 was used for pretargeted RIT in mice bear-
ing CEA-positive colorectal cancer xenografts, where 
α-emitting hapten 213Bi-IMP288 was shown to be at least 
as effective as β-emitting hapten 177Lu-IMP288.
Antibody labeling approaches
Generally, the radiolabeling of antibodies is occurred 
through the use of chelating agents [76–81]. The attach-
ing chelators to antibodies is performed covalently via 
complementary reactive functional groups for the con-
jugation to each other. The N-hydroxysuccinimide esters 
(NHS), isothiocyanates (SCN) and anhydrides can be 
considered as the most conventional reactive electro-
philic groups that can react with the ε-amino group of 
lysines on the antibody at alkaline conditions (pH 7.2–9). 
In such conditions, NHS- or SCN-containing chelators 
can be easily conjugated with antibodies to form strong 
covalent bond. After the chelator attachment is achieved, 
the radiolabeling is occurred via the complexation pro-
cess. However, in case of conjugation reaction using 
NHS- or SCN chemistry, the presence of multiple amino 
acids in antibody structure may lead to a lack of both 
stoichiometric control and site-specificity [82–84]. The 
spontaneous chelator-antibody conjugation can decrease 
affinity for target receptors and provide non-optimal 
pharmacokinetics. Therefore, the development of more 
desirable chemoselective approach to bind chelators with 
antibodies is required and urgent.
The “click chemistry” is found to be powerful method 
for rapid antibody chelation that provides an appropriate 
site-selective conjugation of chelators with antibodies. 
However, this method requires the antibody pre-mod-
ification. There are many examples where the reactive 
“click” groups have been site-selectively introduced into 
antibodies [85, 86]. The site-selective conjugation meth-
ods for preparation of radiolabeled antibodies include the 
modification of cysteines/disulfide bonds and the glycan 
region of the antibody and enzyme-mediated conjugation 
[28].
The cysteine is widely used a single amino acid or thiol-
containing small molecule for antibody modification. 
The most popular method of antibodies conjugation via 
cysteines involves so-called a Michael reaction of a thiol 
groups with a maleimide, resulting in formation of a 
succinimidyl thioether product. The maleimide groups 
have been widely used to incorporate the chelators via 
cysteine thiol groups [28]. However, maleimide-thiol 
modification can be unstable in vivo and, therefore, other 
new cysteine-reactive reagents that provide enhanced 
conjugate stability have been explored including employ-
ing phenyloxadiazole sulfones, dibromomaleimides, and 
dithiophenolmaleimides [87]. Also, monobromo maleim-
ide has been used to generate stable antibody conjugates 
[88].
Considering the glycan region of the antibody, they 
can be chemically modified to provide site-selective 
attachment of chelators. One widely used example 
of such modification includes the generation of an 
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aldehyde group by oxidizing the cis-glycol groups of 
terminal hexoses using sodium periodate [89–91]. 
Further, the generated aldehydes can react with che-
lators, containing amine groups to form stable imine 
conjugates.
The application of enzyme-mediated conjugation 
also provides site-specific binding of chelators to target 
antibodies. This approach involves the use of enzymes 
that recognize two complementary motifs on the anti-
body and the chelator functional groups [85, 92]. The 
enzymes catalases covalent binding of the chelator to 
antibody using these two complementary motifs. The 
β-1,4-galactosyltransferase (Y289L), transglutami-
nase and, sortase A are typical enzymes used in site-
directed enzyme-mediated conjugation of chelators to 
antibodies. Such technique was applied to incorporate 
89Zr-labeled desferrioxamine (DFO) chelator and 64Cu-
labeled 4-(1,4,8,11-tetraazacyclotetradec-1-yl)-methyl 
benzole acid tetrahydrochloride (CPTA) chelator [85, 
93]. Another work described the 18F-labeling reaction 
using sortase [94]. It should be noted that enzyme-
mediated conjugation is occurred under mild condi-
tions that do not denature the antibody.
Besides chelation techniques, the direct radioiodina-
tion of antibodies is a powerful method for the prepara-
tion of antibody-based radiopharmaceuticals [95]. The 
radioiodination can be achieved by directed radiolabe-
ling the iodine radioisotope to tyrosines on the antibody 
or antibody fragment using well-established procedures 
that reported early starting from 1980s [96]. The good 
example of such radiopharmaceutical is tositumomab 
(131I-labeled anti-CD20 antibody), which received Food 
and Drug Administration (FDA) approval for the treat-
ment of Non-Hodgkin’s lymphoma in 2003 [97].
In case of radioactive 18F, the antibody labeling is per-
formed by directed binding to a tyrosine residue via 
electrophilic reaction [98]. Moreover, the incorporation 
of 18F can be achieved via conjugation of 18F-labeled 
reactive precursors, containing prosthetic groups [99].
Another interesting approach of antibody radiola-
beling involves photoradiochemical methods that 
use light-induced antibody modification with chela-
tors derivatized with aryl azide  (ArN3) groups [100, 
101]. Recently, Holland et al. demonstrated the photo-
chemical conjugation of mAbs with 68Ga via an  ArN3 
functionalized 2-[4,7-bis(carboxymethyl)-1,4,7-triazo-
nan-1-yl]pentanedioic acid chelate (NODAGA-PEG3-
ArN3). The method works via a conventional two-step, 
preconjugation and radiolabeling pathway, and also 
by a one-pot, pre-radiolabeling route. As the authors 
reported, the speed and simplicity of this photoradio-
chemical route renders the method suitable for auto-
mation [101].
Outlooks
mAbs were historically first trial instrument to provide 
targeting delivery of bioactive compounds into the site 
of interest. Many radionuclide labeled mAbs are actively 
used for diagnostic and therapy of malignant neoplasms 
while the protein engineering opportunities allows to 
control plasma half-life time and biodistribution param-
eters of radionuclides. As a result, the change of interest 
from the traditional radionuclide-full antibody conju-
gates to the antibody-based fragments is now observed. 
The use of antibody derivates allow to increase the speci-
fity, targeting ability and distribution parameters of radi-
onuclides. Besides, employing bispecific antibodies can 
reduce radioisotope dosage in pretargeting strategy. Also, 
the antibody fragments have great potential as targeting 
ligands for nano- and microparticle based therapeutics 
with the resulting constructs demonstrating enhanced 
selectivity, specificity and pharmacokinetics. Combina-
tion of high specifity of antibodies based targeting ligands 
with high loading capacity of nano- and microparticle 
allows to obtain modern form of radiopharmaceuticals. 
Moreover, the use of NPs as a radionuclide carrier guar-
antee the stability of radionuclide during its delivery and 
save the biological properties of targeting ligands, which 
results in minimizing antibody-radionuclide interac-
tions.  The recent studies on radionuclide delivery using 
antibodies and antibody fragments  were presented in 
Table 1. 
Organic NPs
The organic NPs are actively used to transport various 
kinds of biologically active substances, including radio-
nuclides [102]. At present, many types and variations 
of organic NPs were designed and fabricated. There are 
basically five main categories of organic NPs that have 
been utilized in nuclear medicine for therapy and diag-
nostics: (i) liposomes, (ii) albumin-based NPs, (iii) den-
drimers, (iv) polymeric micelles and (v) polymeric NPs. A 
large number of techniques have been developed for radi-
onuclide labeling and surface functionalization of organic 
NPs by targeting ligands in order to provide addressable 
delivery of radionuclides at the desired site, i.e., tumor 
area. In this section, we consider the organic nanocarri-
ers used for radiolabeling and discuss the principles and 
approaches in targeting ligand modification and radionu-
clides incorporation with appropriate examples (Fig. 4).
Liposomes
Liposomes are phospholipid vesicles with one or more 
bilipid layers that contain an aqueous phase within them. 
They were firstly discovered by Banghman and col-
leagues [103]. The sizes of these carriers can vary from 
the smallest (up to 100  nm) to gigantic (more than 1 
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micron) depending on the methods of synthesis. In the 
case of nanoscale liposomes, their important feature is 
the tendency to accumulate in the tumor tissues, pro-
viding passive drug delivery mechanism [104]. The cur-
rent strategy of radionuclide delivery to the tumor sites is 
based on the active targeting of liposomes via their sur-
face functionalization with specific ligands, i.e. peptides, 
antibodies, small molecules, proteins and so forth [105]. 
As an example, Anti-HER2 antibodies were successfully 
conjugated onto the liposome surface with conventional 
thiol-maleimide chemistry technique to deliver bioac-
tive compounds into HER2-overexpressing tumor [103]. 
Another clinically used target is the EGFR that is consti-
tutively activated in many solid tumors. Recently, Shargh 
and colleagues published the comprehensive review arti-
cle describing the different conjugation techniques for 
preparation of antibody-targeted liposomes [103].
Cell-targeting peptides are also used to conjugate with 
liposomes through covalent bond by a variety of link-
ages (maleimide linkage bond, peptide bond, sulfanyl 
bond, disulfide bond and phosphatidylethanolamine-
linker bond) [106]. For example, Zhang et al. reported on 
liposomes containing cantharidin and a tumor specific 
cell-penetrating peptide BR2. BR2-directed liposomes 
demonstrated enhanced cellular-uptake in hepatocel-
lular carcinoma as compared to non-targeted liposomes 
[107]. Recently, Backer et  al. developed a new method 
for covalent coupling of targeting proteins to liposomes 
via so-called “dock and lock” strategy, which exploits the 
natural interaction between the dimerization and dock-
ing domain that provides “safe” protein conjugation. 
Many small molecules (e.g. folate, affibody, carbohydrate 
and so forth) were used as targeting ligands for function-
alization of liposome surface. However, a recent trend in 
functionalization of liposomes is the combination of pep-
tides and antibodies in a single formulation for surface 
modification. Such dual modification provides enhanced 
selectivity compared to the single type of modification.
In 1993 Goins with colleagues firstly investigated the 
labeling of liposomes with radionuclides [108]. The addi-
tion of radionuclides was performed after the liposome 
formation and not during the liposome synthesis. Then, 
the new methods of radiolabeling with liposomes have 
been developed. Nowadays, four general approaches 
can be highlighted for incorporating radionuclides into 
liposomes: (i) passive encapsulation, (ii) membrane labe-
ling, (iii) surface chelation, and (iv) remote loading via 
lipophilic chelator or ionophore (Fig. 5) [108]. In case of 
passive encapsulation, the radionuclide pre-associated 
with chelator is included in the buffer solution, where 
liposomes are formed. In this method, the incorpora-
tion efficiency of radionuclides does not usually exceed 
10% in case of nanoscale liposomes (< 100  nm), there-
fore, this method is rarely used for incorporation of 
highly cost therapeutic radionuclides such as 225Ac and 
177Lu. According to the membrane labeling, the radionu-
clides can be conjugated to a lipid layer that is formulated 
into the liposomes via simple incubation of liposome 
Table 1 Recently studied radionuclide delivery systems based on antibodies and antibody fragments
Radionuclide Delivery system Labeling Application Comments Refs.
89Z Diabody Chelation (DFO) PET Molecular imaging of CD4+ T cells throughout the body has implications 
for monitoring autoimmune disease and immunotherapy of cancer
[46]
89Z Diabody Chelation (DFO) PET PET based detection of PSMA in prostatic tumor models [48]
177Lu Nanobody Chelation (DTPA) RIT 177Lu-DTPA-2Rs15d nanobody-based targeted radionuclide therapy in 
mice bearing small established HER2 positive tumors led to an almost 
complete blockade of tumor growth
[58]
68Ga Nanobody Chelation (NOTA) PET The described agents were capable of highly specific accumulation in the 
tumor areas and reduced kidney retention comparing to the previously 
reported Nanobodies due to the removal of histidine tag. Overall the 
reported tracer proved to be safe in mouse toxicity and dosimetry stud-
ies and suggested for further clinical trials
[59]
177Lu Affibody  ZHER2:342 Chelation 
(maGGG and 
maGSG)
RIT Successful targeting of HER2 positive microxenografts was confirmed by 
gamma-camera imaging, and the treatment extended survival in mice 
with high and low HER2 expressing tumors. However, overall mortality 
was caused by bone marrow toxicity
[67]
111In bsAbs Chelation (DOTA) SPECT, RIT In a first-in-human Phase I study, anti-CEA with anti-HSG TF2 was evalu-
ated in patients with colorectal cancer, with 111In-IMP288 used in the 
imaging cycle and 177Lu-IMP288 in the following therapy cycle
[73]
213Bi bsAbs Chelation (DOTA) RIT The authors demonstrated the usage of Tri-Fab antibody which allowed 
pretargeting of radiolabeled hapten–peptide IMP-288. In vivo 
α-emitting hapten 213Bi-IMP288 was shown to be at least as effective as 
β-emitting hapten 177Lu-IMP288
[75]
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with radionuclides. The limitation of this approach is 
the instability of liposome radiolabeling because of 
non-covalent bonding of radionuclides with liposome 
membrane. The use of chelating agents for radionuclide 
labeling can improve the stability of radionuclide bid-
ing, but not in all cases. For example, the incorporating 
Fig. 4 The main categories of organic NPs used for radiopharmaceutical formulations with schematic representation of their radiolabeling 
strategies. Below the commonly used macrocyclic and acylic chelators for radiolabeling are depicted
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lipid chelator conjugated onto liposome membrane does 
not provide an appropriate in vivo stability and the radio-
nuclides, which are attached onto the liposome surface, 
interact with the components of the blood stream. This 
may result in the detachment of the radionuclides from 
the liposomes even at the labeling efficiency 90%. In 
general, DOTA and 1,4,7-Triazacyclononane-1,4,7-tri-
acetic acid (NOTA) are widely used chelating agents for 
surface modification of liposomes. The use of lipophilic 
chelating agents such as N,N-bis(2-mercaptoethyl)-Nʹ,Nʹ-
diethylethylenediamine (BMEDA), and hexamethylpro-
pyleneamine oxime (HMPAO), as well as ionophores can 
promote penetration of radionuclides through the lipid 
bilayer, providing a high stability of radiolabeling [109]. 
Moreover, by employing lipophilic chelator or ionophore, 
the radionuclides can be carried through the lipid bilayer 
inside the aqueous phase of liposome, where the radio-
nuclides are bound with pre-loaded metal chelator. This 
concept of radiolabeling has been successfully realized by 
Edmonds et al. Authors developed a simple and efficient 
radiolabeling method providing excellent radiolabeling 
yields, purities, and stabilities with 89Zr, 52Mn, and 64Cu, 
without the modification of the delivery system compo-
nents [110].
The high flexibility of chemical structure and wide 
range of radiolabeling approaches allow to design the 
liposomes for various biomedical applications, including 
multimodal imaging, radiochemotherapy, RIT, α therapy, 
infection and inflammation imaging, neurological imag-
ing and so forth [110]. Recently, Kleynhans et al. reported 
on a detailed description about application of liposomes 
in different fields of nuclear medicine [111].
Apart from conjugation with radionuclides, 
liposomes can additionally modified to provide imaging 
properties. As an example, Kim et al. designed trimodal 
liposomes for optical, nuclear, and magnetic resonance 
imaging (MRI) [112]. These liposomes were capable of 
incorporating 124I emitting both nuclear and optical 
imaging signals, and simultaneously lipophilic gado-






























Fig. 5 Schematic representation of various radiolabeling approaches of liposomes, targeting ligand modifications with further application in 
different field of nuclear medicine
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the theranostic approach, such liposomes could be 
additionally loaded with antitumor drugs (e.g. doxo-
rubicin, vincristine and so forth). The combination of 
therapeutic radionuclides (e.g. 186/188Re) with chemo-
therapeutic agents (e.g. doxorubicin) in one single lipo-
some provided radiochemotherapeutical effect [113, 
114]. Interesting results were obtained for liposomes 
labeled with 225Ac, which is promising therapeutic 
radionuclide for targeted α-therapy [115–118]. An 
example for employment of radiolabeled liposomes in 
visualization of infection and inflammation was dem-
onstrated by Ferreira with co-workers, who developed a 
long-circulating and pH sensitive liposomes containing 
a 99mTc-labeled antibiotic (ceftizoxime) for identifica-
tion of osteomyelitis foci [119]. Also the 99mTc-labeled 
liposomes were used as blood-pool imaging agents 
[120]. A novel application of liposomal 18F is the imag-
ing of synaptic density in the brain by targeting voltage-
dependent calcium channels (N-type  Ca2+). This tracer 
can image neurodegeneration and evaluate cognitive 
function during therapy [121].
The liposome technologies are the most studied 
delivery systems in humans [122]. We refer to recently 
published review articles by Petersen et  al. [108] and 
Lamichhane et al. [123], which highlighted the examples 
of the clinical studies focused on the application of lipo-
somal-based radiopharmaceuticals in nuclear imaging 
using SPECT or PET. For example, Lopez-Berstein et al. 
administrated 99mTc-labeled liposomes to seven can-
cer patients as imaging agents for tumor detection and 
staging [124]. In addition, there are clinical studies with 
111In-labeled liposomes that demonstrated their safety 
and utility for tumor detection [125]. Later, Koukourakis 
et al. performed the first clinical studies of 99mTc-labeled 
liposomes containing a therapeutic drug (doxorubicin) 
on seven patients with Kaposi’s sarcoma and head and 
neck cancer [126]. Recently, Lee et  al. reported a clini-
cal trial of MM-302, a PEGylated liposomal doxorubicin, 
labeled with 64Cu radioisotope targeted against HER2 
 ([64Cu]MM-302) [127]. The 19 patients with metastatic 
breast cancer for imaging study were selected for test-
ing MM-302 radiolabeled with 64Cu. The results from the 
PET imaging (Fig.  6) demonstrated that  [64Cu]MM-302 
remained in the circulation for over 24 h, and thereafter 
accumulated mostly in the liver and spleen.
Another recent example of clinical use of liposomal 
radiopharmaceuticals was performed by the Institute 
of Nuclear Energy Research (Taiwan) that has already 
advanced a lipid theranostic agent into Phase I clinical 
testing (clinical trial NCT02271516). The tested lipo-
some system was radiolabeled with 188Re as therapeutic 
and diagnostic isotope linked to BMEDA, which acts 
as a chelating agent. These 188Re-BMEDA liposomes 
exhibited a higher therapeutic efficacy in rodent xeno-
grafts [111].
Albumin‑based NPs
The albumin is a major protein in blood plasma and 
actively used in formation of albumin-based drug deliv-
ery systems because of selective accumulation into the 
solid tumor via so-called the enhanced permeation and 
retention (EPR) effect [128]. At the moment, there is 
already existed the first albumin based antineoplastic 
agent approved by the FDA, which is called Abraxane. 
Especially, human serum albumin (HSA) and bovine 
serum albumin (BSA) have driven extensive research 
in nuclear medicine [129]. Since the HSA molecule is 
more preferable than BSA for further preclinical and 
clinical application due to the low immunogenicity, we 
further review only HSA-based formulations. The HSA 
molecule has active chemical centers for radionuclide 
labeling (carboxyl, amine and thiol groups) [130]. HSA 
was covalently labeled with various radionuclides (68Ga, 
64Cu, 89Zr and so forth) by employing different chelators. 
99mTc-labeled macroaggregated albumins are already 
commercially available as SPECT imaging agents such 
as 99mTc-Pulmolite® and 99mTc-HSA microspheres  B20® 
for lung perfusion imaging; 99mTc-Albures® for liver and 
spleen imaging and 99mTc-Nanocoll® as well as 99mTc-
Nanotop® for bone marrow and sentinel lymph node 
(SLN) imaging. Several techniques can be employed for 
effective radiolabeling of albumins. Usually, introduction 
of macrocyclic or acyclic chelators (DOTA, DTPA) into 
albumin structure is used to achieve the desired stabil-
ity and suitable pharmacokinetic properties. Another 
promising approach to label radionuclides with HSA is 
the employment of low molecular weight albumin-bind-
ing molecules (HSA binders), which were further iden-
tified as reversible albumin binders. These HSA binders 
possess a high affinity towards HSA and can be coated 
with targeting ligands and radionuclides, forming HSA-
binding conjugates. The concept of using reversible 
HSA-binders to modulate the blood circulation time and 
hence the pharmacokinetic profile of radiolabeled mol-
ecules was adapted and applied by other groups [128]. 
Besides HSA in an individual form, the radionuclide 
(usually 99mTc) labeled HSA aggregates are widely used 
in clinics. For example, 99mTc-labeled HSA-based NPs 
were prepared by radiolabeling of 99mTcO4− to protein 
using  SnCl2 as the reducing agent at a wide pH range of 
3.8–8.0 [131]. The size of formed HSA-based aggregates 
depended on the amount of initial reagents and reaction 
time, and varied from nanometers to micrometers. The 
HSA-based NPs, which are generally formed via cross-
linking reaction with glutarealdehyde, can be decorated 
with active targeting ligands and simultaneously labeled 
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with radionuclides. The radiolabeling HSA-based NPs 
were also prepared using 99mTc(CO)3+ precursor, pos-
sessing the high affinity binding to the histidine residues 
on the protein surface [132]. The more recent method 
for obtaining radiolabeled HSA NPs was reported by 
Charkavarty et  al. [133]. Authors developed one-pot 
synthesis protocol fabrication of small sized (4–5  nm 
diameter), water-soluble, intrinsically radiolabeled 64Cu 
metal NPs capped within HSA. The synthesis was based 
on the formation of strong complex between Cu and 
HSA at pH ~ 12 with the following heating at ~ 55 °C that 
led to the formation of 64Cu-HSA nanocomposites. Also 
Tian with co-workers developed 131I-labeled HSA coated 
manganese dioxide NPs through the mixing HSA solu-
tion with manganese chloride forming HSA-MnO2 NPs 
with further labeling radionuclide 131I using a standard 
iodogen oxidation method [134].
Currently, there is a significant interest in fabrication 
of multifunctional HSA delivery systems, which combine 
several properties in one drug carrier. For example, HSA-
based NPs can simultaneously contain contrast agents for 
MRI imaging, radionuclides for PET, antitumor drugs for 
combined thermotherapy and targeted ligands for active 
targeted delivery.
Dendrimers
Dendrimers can be considered as well-defined monodis-
perse and globular nanovectors, possessing explicit archi-
tecture and composition with highly controllable size 
and surface properties [135]. They consist of a core and 
several layers with active terminal groups. The Vögtle, 
Newkome, and Tomalia scientific groups firstly reported 
on dendrimers in the late of 1970s and early 1980s inde-
pendently. Nowadays, the application of dendimers in 
Fig. 6 PET and PET/CT images of  [64Cu]MM-302 in lesions at different anatomic locations. The regions of interest used to measure tumor deposition 
of  [64Cu]-MM-302 are shown in blue or turquoise outlines (this figure was reproduced from Lee et al. [127] with the required copyright permission)
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biomedicine as drug delivery platform is rapidly grow-
ing. The design principle of dendrimers, including sur-
face/interior chemistry, size generation, shape, flexibility 
and composition, has been comprehensively reviewed 
and described in the work [136]. Various types of den-
drimers including polyamidoamine (PAMAM), poly-
propyleneimine (PPI), poly(glycerol-co-succinic acid), 
poly-l-lysine (PLL), melamine, triazine, poly(glycerol), 
poly(2,2-bis(hydroxymethyl)-propionic acid) and PEG, 
as well as carbohydrate-based and citric-acid-based ones, 
have been developed as drug delivery platforms [137–
140]. Among them, PAMAM- and PPI-based dendrimers 
have been some of the most widely investigated vectors 
that have gained tremendous attention [141]. The sur-
face of dendrimers is rich of reactive (terminal) groups, 
which can be functionalized with targeting ligands. A 
wide selection of ligands (biotin, folic acid, amino acids, 
peptides, aptamers and mAbs) was successfully conju-
gated with dendrimers surfaces. The biodistribution of 
dendrimers has been investigated by administration of 
radiolabeled dendrimers in animals. The charge of den-
drimers has a significant impact on the biodistribution 
and toxicity of dendrimers. As demonstrated, the cati-
onic dendrimers possess low circulation times compared 
to anionic dendrimers [142]. Moreover, the cationic den-
drimers were more toxic than anionic dendrimers, which 
can be related with membrane disruption due to interac-
tions with negatively charged cell membranes [143].
Considering the physical half-life of radionuclides and 
radiolabeling strategies, dendrimers are mainly modi-
fied with chelators attached to the surface with further 
labeling with radionuclides (post-labeling approach) 
[144]. Medically relevant radionuclides were success-
fully applied to form stable dendrimers-radionuclide 
conjugates. Most of the data are associated with the pre-
clinical studies of radiolabeled dendrimers. For example, 
PAMAM dendrimers functionalized with 10-[(4-car-
boxy-1-oxidopyridin-2-yl)methyl]-1,4,7,10-tetraazacy-
clododecane-1,4,7-triacetic acid  (H4do3a-pyNO-C) can be 
mentioned. This formulation was used for radiolabeling 
with 177Lu with high radiochemical purity [145]. The 
pioneering work in dendrimer radiolabeling was per-
formed by Mukhtar et  al., who synthesized two water 
soluble dendritic porphyrins for radiolabeling with 99mTc 
[146]. Agashe et  al. also showed the potential of 99mTc-
labeled dendrimers using PPI dendrimers for the biodis-
tribution investigations [147]. For solely nuclear imaging 
purposes, dendrimers were radiolabeled with 76Br to 
monitor angiogenesis using PET imaging [148]. It should 
be noted that radiolabeling with dendrimers could occur 
at room temperature [149]. Recently, Garrigue et  al. 
reported on self-assembling supramolecular dendrim-
ers bearing NOTA for complexing with 68Ga [150]. The 
68Ga-labeled dendrimers showed an effective tumor tar-
geting in case of prostate, glioblastoma, colorectal and 
pancreatic cancers. The radionuclide-based theranostic 
dendrimers labeled with radionuclides emitting both β 
and γ rays simultaneously (177Lu, 131I, 188Re) were inves-
tigated in References [151–154]. For instance, the thera-
nostic 131I-labeled PAMAM dendrimers modified with 
PEG and chlorotoxin (CTX) as the targeting agent were 
employed for targeted SPECT imaging and radiotherapy 
of a matrix metalloproteinase-2 (MMP-2) overexpress-
ing xenografted glioma model in vivo [152]. It should be 
noted that iodinated dendrimers are excellent computer 
tomography (CT) contrast agents, what suit for multi-
modal imaging (combination of SPECT with CT). The 
188Re-labeled PLL dendrimers (ImDendrim) is into Phase 
I clinical testing (clinical trial NCT03255343) for treat-
ment of colorectal cancer.
For improved diagnosis accuracy, two or more modali-
ties of contrast imaging are combined to overcome the 
disadvantages of each individual technique. For this 
reason, radionuclide-labeled dendrimers conjugated 
with other imaging agents (e.g. fluorescent moieties). 
The development of dual SPECT/fluorescence imag-
ing dendrimers platform is quiet useful, because radio-
nuclide-based SPECT imaging allows increased depth 
penetration whereas near infrared (NIR) optical imag-
ing provides excellent real-time spatial resolution. Urano 
et al. employed a PAMAM dendrimer platform that can 
be linked to both radionuclides and optical probes, ena-
bling dual-modality scintigraphic and five-color NIR 
optical lymphatic imaging [155]. In case of PET/NIR 
optical imaging, Wang et  al. developed PAMAM den-
drimer platform simultaneously conjugated with 64Cu 
and NIR fluorescence-emitting dye Cyanine5.5 (Cy5.5) 
for dual-modality imaging of ovarian cancer [156].
Polymeric micelles
The polymeric micelles are defined as organized self-
assembly composed of amphiphilic macromolecules 
(amphiphilic, di- or tri-block copolymers) in a block-
selective solvent [157]. They consist of a hydrophobic 
core and hydrophilic corona shell, exhibiting a wide range 
of sizes (usually 5–100 nm). As described in many works, 
the hydrophobic core serves as anchors for poorly water 
soluble drugs. The polymeric micelles possess the ultra-
stability and can accumulate in tumor tissue through the 
EPR effect. A number of polymeric micelles with various 
structural organization as carriers for anticancer thera-
peutic and diagnostic agents was reported in literature 
[157].
Similar to other delivery systems, polymeric micelles 
can be functionalized with targeting ligands. Commonly 
used ligands are mAbs, carbohydrate moieties, aptamers, 
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proteins, and peptides [158]. Widely used targets include 
the EGFR, Her2, folate receptor, and PSMA.
To incorporate radionuclide in micelle structure, the 
chelation techniques can be employed. In 1995, Tru-
betskoy and Torchilin firstly incorporated amphichilic 
chelating agents such as DTPA-phosphatidylethanola-
mine (DTPA-PE) and DTPA-stearylamine (DTPA-SA) 
into PEG-modified micelles and used these micelles for 
γ-scintigraphy of the lymphatic system after subcutane-
ous administration in rabbits. Nowadays, with the devel-
opment of micelle fabrication, the different chelators for 
the radionuclide labeling can be easily conjugated with 
the end-groups of micelle polymeric shell. Mainly, the 
radiolabeling of polymeric micelles is occurred on the 
hydrophilic shell, while hydrophobic drugs are encapsu-
lated in the core of the micelles. In this case, post-labeling 
approach is used, when chelators (DTPA or DOTA) are 
conjugated to the hydrophilic corona shell and further 
bind the radionuclides. Also, radionuclides can be encap-
sulated in the hydrophobic core of the micelles using a 
lipophilic radionuclide-ligand complex during the micelle 
formation. The micelles are usually functionalized with 
diagnostic radionuclides such as 18F [159, 160], 111In 
[161–164] and 64Cu [165–167] for further evaluation of 
in  vivo biodistribution and targeting efficiency. There 
are only a few works, where micelles were labeled with 
therapeutic radionuclides such as 90Y [168], 131I [169]. 
The micelles loaded with γ emitters (99mTc and 111In) 
have extensively been investigated for in  vivo biodistri-
bution studies using SPECT imaging [162, 170]. Another 
more relevant example was reported by Miura, who 
developed DOTA-functionalized polymeric micelles for 
labeling with 111In [171]. Later, Jensen with co-workers 
developed triblock PEG‐pHEMA‐PCMA micelle modi-
fied with macrocyclic chelator 2,2′‐(1,4,8,11‐tetraazabicy-
clo[6.6.2]hexadecane‐4,11‐diyl)diacetic acid (CB‐TE2A) 
using pre-labeling approach for complexation with radio-
isotope 64Cu. The conjugation of CB‐TE2A chelator was 
performed to the primary alcohols of the pHEMA block 
through 4‐dimethylaminopyridine–catalyzed 1‐ethyl‐3‐
(3‐dimethylaminopropyl)carbodiimide coupling in 
dimethylformamide (DMF) [172].
In clinical trials polymeric micelles received authori-
zation for evaluation mainly as anticancer drug car-
riers [173]. Almost all of them can be prepared by 
self-assembly of amphiphilic block copolymers contain-
ing hydrophilic PEG blocks and hydrophobic polyester, 
poly(aspartic acid), or poly(glutamic acid) blocks. The 
drug molecules used in these systems are mostly classical 
cancerostatics (paclitaxel, camptothecin and its analogue 
doxorubicin, or platinum complexes). Paclitaxel loaded 
polymeric micelles (Genexol PM) have reached the most 
advanced testing stages and received approval for the use 
in Europe and Korea for the treatment of breast and small 
cell lung cancer. Ulbrich et al. gave a clear description on 
clinical studies of polymeric micelles as anticancer drug 
carriers used in cancer therapy [173]. As mentioned 
above, the hydrophobic core of micelles is preferable for 
incorporating of hydrophobic drugs while hydrophilic 
corona shell suits for radiolabeling. From this point of 
view, these so-called theranostic micelles are generally 
considered as multifunctional platform that combines 
drugs and imaging agents for PET or SPECT.
Polymeric‑based NPs
Polymeric-based NPs can be defined as solid polymer 
particles or aggregates (micro- and nanosized ranges), 
where the bioactive compounds are encapsulated into 
the polymer matrix or coated with the surface of poly-
mer NPs. There is no real classification of polymeric NPs 
and each literature review uses its own grouping. In this 
section, we did not include polymeric micelles, which 
have already been described above. The polymeric NPs 
are currently applying for different biomedical purposes, 
including drug and gene delivery, tissue engineering, bio-
imaging and so forth [174]. They are able to form highly 
stable complexes with radionuclides as well as permit a 
rapid labeling of targeting ligands. The techniques of 
incorporating radionuclides into polymer structure were 
adapted from the strategies for radiolabeling of proteins. 
In general, pre-labeling and post-labeling approaches 
are used for incorporating radionuclides with chelating 
agents. As for the pre-labeling method, the radionuclides 
are conjugated with chelating agent before their attach-
ment to the polymer structure. In case of post-labeling 
approach, the polymeric NPs can be decorated with 
chelators via conjugation reaction or polymerization of 
monomers before their radiolabeling [173]. The DOTA 
and DTPA are most frequently used chelators that dem-
onstrated high stability complexation with 68Ga, 64Cu and 
111In. The attachment of chelating agents to the polymer 
structure is usually achieved via functional groups in che-
lators that can react with free amines (active esters, iso-
thiocyanates), sulfhydryl- (maleimides, iodoacetamides), 
carboxylate- (amines, alcohols) or alkynyl- (azide) groups 
of the polymer to form stable polymer-chelator conju-
gates [80]. The classical organic iodination procedure 
is applied for polymer radiolabeling. The direct electro-
philic iodination of tyrosine residues using so-called the 
Bolton–Hunter reagent (i.e., radiolabeled N-succinimi-
dyl-3-(4-hydroxyphenyl) propionate) can be considered 
as the mostly varied radiolabeling method in case of pol-
ymer-based structures. Another smart and straightfor-
ward method for radiolabeling of polymeric NPs involves 
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the formation of polyvinyl phenol particles surrounded 
by PEG [175]. The polyvinyl phenol is able to form a sta-
ble core, where 125I radionuclides can be introduced via 
electrophilic aromatic substitution.
Polylactic acid (PLA), polyglycolic acid (PGA) or their 
copolymer poly(lactic-co-glycolic acid) (PLGA) belong to 
the most advanced biodegradable polymers used in the 
preparation of polymer-based nanocarriers. Moreover, 
PLGA and PGA are already approved by FDA for clinical 
use in macroformulations. The surface of polymeric NPs 
is frequently coated with hydrophilic polymers (e.g. PEO) 
to prevent the adsorption of plasma proteins. In case of 
nuclear imaging, radionuclides such as 11C, 18F, 64Cu, 
76Br, 99mTc, 111In, and 90Y have been used with a wide 
range of synthetic polymers to formulate nanosized car-
riers [159, 176, 177]. For example, the PLGA NPs, labeled 
with 99mTc, are successfully used in diagnostics for imag-
ing of lungs [178] and sentinel lymph nodes [177]. 111In-
labeled galactosylated PLGA NPs have been developed as 
trackable carriers for the liver specific delivery of drugs 
[179]. Sirianni et  al. developed radiolabeled PLGA NPs 
with biotinylated 18F prosthetic groups for their track-
ing imaging using PET [180]. As for PLA, Banerjee et al. 
fabricated PSMA-targeted PLA-based NPs radiolabeled 
with 111In for SPECT imaging of PSMA-expressing tis-
sues [181].
Natural polymers such as chitosan and dextran are also 
actively used for delivery of diagnostic radionuclides. 
Various formulations based on radiolabeled chitosan 
were reported. The 99mTc/131I-labeled water-soluble chi-
tosan derivatives were used as SPECT/PET imaging 
agents [182]. Akhlaghi et al. performed the radiolabeling 
of chitosan derivatives with 66Ga using chelator DTPA. 
The use of DTPA for complexation with 66Ga allowed 
to achieve the highest efficiency to prevent radionuclide 
leakage [183]. Also, Lee et  al. reported a facile method 
to label PEOylated-chitosan NPs with 64Cu, using azide-
functionalized chitosan and DOTA derivatives with 
appending dibenzyl cyclooctyne moieties. This formu-
lation allowed fast labeling (~ 30  min) with high radi-
olabeling yield (98%) and showed a tumor uptake in 
adenocarcinomic human alveolar basal epithelial cells 
(A549) tumor-bearing mice. The nanosized glycol chi-
tosan NPs were labeled with 64Cu via copper-free click 
reaction for study of in vivo biodistibution. The dextran 
is also effectively used for targeted delivery of radionu-
clides. Moreover, dextran-based carriers was proved 
to be effective in clinical studies (Phase I and II), and a 
clinical Phase III study with oral cavity squamous cell 
carcinoma patients confirmed the detection and accurate 
prediction of the pathologic nodal status with 0% false 
negative results [184].
Outlooks
At present moment, most of the described organic based 
NPs are used to optimize radionuclide delivery: increase 
circulation time, avoid non-specific activity and provide 
tumor accumulation. The advances in surface chemistry 
enable different functionalization of organic NPs with 
targeting ligands. Several issues should be taken into 
account before implementation of organic NPs into clin-
ics. First, the appropriate and convenient approach of 
radiolabeling should be provided to guarantee sufficient 
radiochemical stability. Second, radiolabeling should 
not influence the particle size, shape, surface charge and 
composition in order to provide optimal pharmacokinet-
ics and biodistribution. Besides, the individual charac-
teristics of radionuclide carriers should be additionally 
considered: biocompatibility, biodegradability, utilization 
of NPs components and their cytotoxicity.  The recent 
studies on radionuclide delivery using organic NPs were 
presented in Table 2. 
Inorganic NPs
Another type of radionuclide delivery system is NPs of 
inorganic nature. Such NPs can consist of different inor-
ganic materials with the sizes ranging from the nanome-
ters to micrometers [185]. The composition and structure 
of the NPs core determine their unique properties. For 
example, the use of gold NPs (Au NPs) as a core makes 
it possible to perform X-ray and photoacoustic imag-
ing using such delivery systems. Whereas the utilization 
of an iron core allows NPs to be used for MRI imaging 
(Fig. 7) [186]. Despite the unique physicochemical prop-
erties of NPs and their diagnostic potential, the use of 
such carriers for the delivery of radionuclides in clinical 
practice is rather limited. It is associated with undesired 
toxicity, low targeting efficiency, short circulation time in 
the bloodstream and so forth [187]. In this regard, only 
a few inorganic NPs-based delivery systems reached the 
stage of clinical research [188].
Plasmonic and magnetic NPs (Au,  Fe3O4)
Au NPs are widely used in biology and medicine as 
drug delivery carries due to their unique optical prop-
erties [194]. Indeed, pronounced localized surface 
plasmon resonance allows their visualization possibil-
ity in  vitro and in  vivo using photoacoustic [195] and 
X-ray imaging [196]. Optical properties of Au NPs 
strongly depend on their physicochemical composition. 
The modern chemical synthetic techniques allow fabri-
cation of monodispersed Au NPs with well-defined size 
and shape [197]. Recently, Au NPs were also employed 
as core-particles for radionuclides in radiotherapy and 
radiodiagnostics.
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Similar to the organic NPs, in order to achieve target-
ing properties of Au NPs-based radionuclide delivery 
systems, different moieties such as peptides, antibodies, 
aptamers, nucleic acids are employed. These multifunc-
tional platforms allow targeted delivery of radionuclides 
with visualization of radionuclides biodistribution by 
PET/CT or SPECT. In the recent study, 45  nm Au NPs 
were integrated with radioactive 125I. Navigation of Au 
NPs-based radionuclide delivery platform to the tumor 
site was provided by conjugation of Au NPs surface with 
cyclic Arg-Gly-Asp peptide. In  vivo investigation of the 
developed delivery system revealed acute apoptosis and 
tumor growth suppression of NCI-H446 tumor-bearing 
mice after 2 days post treatment [198]. In another in vitro 
comparative study authors employed 30 nm Au NPs con-
jugated with mAbs (panitumumab), which target breast 
cancer (BC) cells overexpressing EGFR. 177Lu was used as 
radioactive compound in Au-based delivery system. The 
obtained data showed that the EGFR overexpressing cells 
demonstrated lower viability than BC cells with lower 
EGFR expression [199]. McLaughlin et al. used so-called 
α generator based on Au NPs to target biologically rel-
evant receptors. In particular, female BALB/c mouse was 
used as a model for the targeted delivery of radionuclides. 
Table 2 Recently studied radionuclide delivery systems based on organic NPs
Radionuclide Delivery system Labeling Application Comments Refs.
124I Liposomes Hexadecyl4-iodo benzoate PET, MRI, optical imaging Kim et al. have prepared a trimodal liposome 
for optical, nuclear, and magnetic resonance 
imaging with fast clearance from reticuloen-
dothelial systems, which enables vivid tumor 
imaging with minimum background
[112]
186Re Liposomes Chelation (BMEDA) Combination of chemo- 
and radiotherapy
186Re-Doxil liposomes were used in combined 
therapy for the treatment of solid tumors
[114]
64Cu Liposomes Chelation (4-DEAP-ATSC) PET Novel 64Cu-MM-302 were used to quantify EPR 
effect in 19 metastatic breast cancer patients 
in order to evaluate the effectiveness of further 
treatment with nanoparticles
[127]
64Cu HSA-based NPs Neutron activation route PET Chakravarty R. et al. developed a one-pot 
synthesis of small sized (4–5 nm diameter), 
water soluble, intrinsically radiolabeled 64Cu 
metal nanoparticles capped within human 
serum albumin (HSA) scaffold (64Cu-HSA 
nanocomposite). Studies in melanoma tumor 
bearing mice showed rapid accumulation of 
the radiotracer in tumor with high tumor-to-
background contrast
[133]
131I HSA-based NPs Iodogen oxidation method RIT, SPECT HSA-bound manganese dioxide nanoparti-
cles (131I-HSA-MnO2) are developed as a RIT 
platform that is responsive to the tumor 
microenvironment. The acidic TME can trigger 
degradation of  MnO2 and thus decomposi-
tion of nanoparticles into individual 131I-HSA 
with sub-10 nm sizes and greatly improves 
intratumoral diffusion
[134]
111In Dendrimers Chelation (SCN-Bz-DTPA) SPECT, optical imaging Kobayashi et al. synthesized nanoprobes with 
multimodal and multicolor potential, which 
employed a polyamidoamine dendrimer plat-
form linked to both radionuclides and optical 
probes, permitting dual-modality scintigraphic 
and five-color near-infrared optical lymphatic 
imaging using a multiple-excitation spectrally 
resolved fluorescence imaging technique
[155]
125I Polymeric-based NPs Iodination via aromatic 
electrophilic substitution
PET, SPECT Tang et al. produced polymeric NPs using Flash 
NanoPrecipitation and radiolabeled them with 
125I at high radiochemical yields (> 90%). The 
nanocarriers demonstrated extended circula-
tion half-lives and gradual RES clearance
[175]
64Cu Polymeric micelles Chelation (CB‐TE2A) PET Jensen et al. investigated the novel triblock 
PEG‐pHEMA‐PCMA micelle modified with 
macrocyclic chelator and difference of in vivo 
biodistribution of cross-linked an non cross-
linked micelles using PET
[172]
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In this case, multiple α radiations were emitted by the 
225Ac daughters while targeting the receptors in  vivo. 
Such radioactive generators can potentially enhance the 
efficiency of tumor therapy [200]. Au NPs can appear not 
only as a core element for the radionuclide delivery plat-
form, but as radioactive part of the system as well. Katti 
et  al. demonstrated a novel approach to treat prostate 
cancer with 198Au NPs, which were modified with gluco-
side molecules mangiferin. In vivo experiments on severe 
combined immunodeficient (SCID) mice revealed over 
85% reduction of bearing prostate tumor volume as com-
pared to the control groups [201].
Superparamagnetic iron oxide NPs (SPIONs) are also 
widely used as a core element for the delivery of radionu-
clides. SPIONs are biocompatible and clinically approved 
NPs [202], which enable real-time visualization of drug 
biodistribution with MRI. Similar to Au NPs, SPIONs 
can be synthesized of various shape and size that affect 
their MRI contrast [203], as well as interaction with cells 
and tissues [204]. Such different behavior was demon-
strated by Radovic et al. in vivo on example of 90Y labeled 
differently sized and coated SPIONs. The biodistribution 
of magnetic NPs was probed on Wistar rats. The data 
revealed that uncoated SPIONs end up in liver in a lower 
rate compared to PEGylated NPs [205]. Targeting fea-
tures of  Fe3O4-based radionuclide delivery systems can be 
achieved either by surface functionalization or by apply-
ing magnet in the close proximity to cells. The latter pos-
sibility was discussed in the recent work, where magnetic 
NPs were modified with 165Ho and cytostatic drug, and 
Fig. 7 Schematic illustration of multimodal imaging of radiolabeled inorganic NPs: plasmonic NPs for X-ray visualization, magnetic NPs for MRI 
visualization, C-based for optical imaging. Si-based NPs requires additional functionalization by contrast agents to be visualized (this figure is 
adopted from Yu et al. [189], Wang et al. [190], Liu et al. [191], Phillips et al. [192], Hoffman et al. [193] with required copyright permission)
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navigated into tumor area using external magnet. In vitro 
and in vivo results suggested that the external magnetic 
field navigation was achieved, since higher amounts of 
165Ho were observed in tumor than in liver, which led to 
the inhibition of tumor growth [206]. In another study, 
radioisotope 125I was integrated into  Fe3O4-Ag heter-
odimer to achieve dual-modality imaging with MRI and 
CT. The obtained delivery platform showed high radi-
olabeling efficiency as well as reduced T2-MRI signal 
intensity [207]. Recent work demonstrated radiolabeling 
of  Fe3O4 NPs of 20  nm size with sodium pertechnetate 
(99mTc- pertechnetate) and the developed system was 
probed on male Wistar rats. The obtained results showed 
that this type of NPs could be introduced in the labora-
tory animals via intravenous injection and biodistribu-
tion could be controlled by external magnetic field [208]. 
Isotope 59Fe can be also used as radioactive element 
incorporated into the crystal lattice of  Fe3O4 NPs. An 
advantage of this approach was the fact that radioactive 
59Fe did not alter MRI contrast properties of  Fe3O4 NPs. 
Therefore, the developed carriers enabled bimodal visual-
ization (MRI/CT) as demonstrated in vivo (Fig. 8) [193].
Fig. 8 Schematic illustration of SPION-based NPs fabrication (top), sagittal MR images of mouse animal model (bottom). The blue arrows indicate 
the brain, the red arrows indicate the liver and the yellow arrows indicate the bladder (this figure is reproduced from Hoffman et al. [193] with 
required copyright permission)
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Silica‑based NPs
Silica NPs are already widely used as delivery carriers of 
various bioactive compounds due to the tailored physico-
chemical properties [209]. One of the great advantages of 
silica NPs is its porosity and, thus, high surface area, what 
makes Si NPs good candidates for employment as drug 
carriers. Silica NPs are usually prepared using chemi-
cal synthesis with a good possibility of size, shape and 
pore-size variation [210]. It is worth noting that some of 
silica-based materials are approved by Food and Drug 
Administration and generally recognized as safe [211]. 
Therefore, unlike plasmonic NPs, ultrasmall 124I modi-
fied silica-based NPs (‘C dots’) were already employed in 
clinical studies in 2014 on humans. Phillips et  al. [192] 
developed radionuclide Si-based carriers, which pos-
sessed dual imaging properties: PET/SPECT and optical 
(due to the additional labeling with fluorescent markers). 
The obtained results on metastatic melanoma patients 
revealed good in vivo particle stability and their distinct, 
reproducible pharmacokinetics without any adverse 
effects. The development of Si-based NPs ‘C dots’ was 
continued in the work by Chen et  al. [212]. They were 
able to optimize the synthesis of carriers in water and 
fabricated a novel PEGylated ultrasmall silica particles 
labeled with Cy5 dye. Si-based NPs were further conju-
gated with chelators and anti-HER2 scFv fragments. This 
allowed to achieve more efficient tumor-targeting with 
bulk renal clearance, which surpasses already existing 
characteristics of scFv molecules and scFv-conjugated 
NPs larger than 10 nm. The experiments were conducted 
in  vivo on BT-474 tumor-bearing mice and revealed a 
favorable pharmacokinetics and clearance with decreased 
hepatic and reticuloendothelial system uptake (Fig. 9).
Prior first clinical trials of Si-based radionuclide-
labeled carriers, series of pre-clinical studies were con-
ducted. For example, mesoporous silica NPs of 400  nm 
size were used to transport stable isotope 166Ho in mice 
with orthotopic non-small cell lung cancer A549-lucif-
erase expressing tumor. The administration of the deliv-
ery systems were intravenous and biodistribution was 
monitored using luciferase bioluminescence [213]. Pas-
cual et  al. improved targeting properties of developed 
Si-based systems by functionalization of NPs with Mucin 
1 aptamer that is specific to breast cancer. Pronounced 
targeted delivery of 99mTc into tumor of MDA-MB-231 
tumor-bearing Balb/c mice was shown and monitored 
with SPECT and bioluminescence options [214]. In 
another study silica NPs were modified with anti-HER2 
and labeled with 99mTc. Antibody conjugation allowed 
to target breast carcinoma cells. Radionuclides delivery 
efficiency was probed in vivo on tumor xenograft mod-
els in mice. Biodistribution of the developed radioactive 
formulation was monitored with optical fluorescence 
microscopy due to the additional labeling of Si-based car-
riers with indocyanine green (ICG) [215].
It is worth mentioning that mesoporous silica NPs 
can be simultaneously loaded with various cargoes. For 
example, in the recent study, mesoporous silica NPs were 
loaded with 89Zr and photosensitizer Chlorin e6, which 
can be activated by Cherenkov radiation from 89Zr. 
Therefore, the developed radionuclide delivery systems 
overcame the limitations of conventional photodynamic 
therapy, which requires light source to activate photosen-
sitizer [216].
Carbon‑based NPs
Carbon-based nanomaterials, which include fullerenes, 
carbon nanotubes (CNTs), carbon dots (CDs), nanodia-
monds, graphene and its derivatives, are of significant 
interest nowadays due to unique optical, thermal and 
mechanical properties [217]. These materials can be used 
as drug delivery carriers, which can be simultaneously 
visualized by fluorescence microscopy [218]. However, 
there are some concerns about toxicity and biocompat-
ibility of carbon-based materials. For example, due to the 
high hydrophobicity and non-biodegradability of CNTs, 
they possess reduced biocompatibility, what can limit 
their applications in biology and medicine [219]. It has 
significant importance in the field of nuclear medicine 
due to the reduced clearance of the radionuclides, what 
can increase the toxic effect of fabricated radioformula-
tion. In order to overcome above mentioned drawbacks, 
the surface of CNTs can be functionalized with biocom-
patible polymers to improve their solubility and biocom-
patibility, thus, reduce their toxicity [220]. Therefore, 
recently single-walled CNTs were successfully employed 
to deliver radionuclides into cells. In this study, the sur-
face of CNTs was simultaneously modified with tumor-
specific mAbs, chelating agent (for radiolabeling with 
111In) and fluorescence markers. The biodistribution 
111In labeled CNTs was possible to monitor with fluo-
rescence microscopy. Such multifunctional CNT-based 
delivery platform demonstrated effective targeting fea-
tures with simultaneous visualization due to fluorescent 
moieties [221]. In another study, surface of single-walled 
CNTs was modified with biantennary carbohydrates 
in order to increase biocompatibility and solubility of 
CNTs. The cavities of CNTs were filled with  Na125I and 
the developed CNT-based radiocarriers were intrave-
nously administered in mice and tracked with CT. It has 
been demonstrated that the tunability of CNT surface 
modification offers versatility of organ specific delivery 
of radionuclides [222]. Ruggiero et  al. developed CNT-
based carriers to deliver 225Ac into the tumor angiogenic 
vessels, which express the monomeric vascular endothe-
lial-cadherin. Antibody and chelating molecules coating 
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significantly decreased toxicity of the delivery platform as 
shown in the murine model [223].
Likewise CNTs, pristine graphene and graphene oxide 
(GO) can induce certain toxicity, however, surface coating 
of graphene and GO by biocompatible polymers reduces 
their toxic effects [224, 225]. Therefore, graphene-based 
materials have been also successfully employed to deliver 
radionuclides in  vitro and in  vivo. Indeed, in the recent 
study Chen and co-workers developed graphene-based 
radionuclide carriers (131I) coated with PEG to reduce 
their toxicity. Synthesized delivery platforms demon-
strated increased efficiency against cancer cells compared 
Fig. 9 In vivo HER2-targeted PET imaging in xenograft breast cancer models. Serial coronal and axial tomographic PET images acquired at 2, 
24, 48, and 72 h post i.v. injection of radiolabeled particle immunoconjugates in groups of tumor-bearing mice as follows: a Targeted group: 
89ZrDFO-scFv-PEG-Cy5-C’ dots in BT-474 mice. b Non-targeted group: 89Zr-DFO-Ctr/scFv-PEG-Cy5-C’ dots in BT-474 mice. For each group, maximum 
intensity projection (MIP) images were also acquired at 48 h p.i. H: heart, B: bladder, L: liver. c Representative MIP PET, CT, and PET/CT fusion images 
of 89Zr-DFO-scFv-PEG-Cy5-C’ dots in a BT-474 tumor-bearing mouse. BT474 tumors are marked with yellow arrows (this figure was reproduced from 
Chen et al. [212] with the required copyright permission)
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with the free 131I isotopes [226]. Surface functionalization 
can not only reduce toxic effects of graphene materials 
but also increase affinity of radionuclide labeling. Indeed, 
non-covalently PEGylated GO nanoplatelets demon-
strated increased labeling with 166Ho [227]. In another 
work, Zhao et al. proved that polydopamine surface func-
tionalization of GO resulted in enhanced adsorption of 
U(VI) [228].
Other carbon-based material, nanodiamonds, is gen-
erally considered to be non-toxic and biocompatible 
in various cell types [229]. Therefore, this material can 
potentially be a good candidate to deliver radiothera-
peutics into cells and tissues. Rojas et  al. labeled nano-
diamonds with functionalized amino groups with 18F and 
monitored the biodistribution of developed systems in 
rats and mice. Authors observed changes in the biodistri-
bution of the developed formulations by the addition of 
surfactant agents in suspension of nanodiamonds, [230]. 
In another study, aminated nanodiamonds were modified 
with 223Ra and 211Pb radionuclides with the 93% and 94% 
of labeling efficiency respectively [231].
Inorganic NPs labeling approaches
While radiolabeling of antibodies and organic nanopar-
ticles is mostly limited to the use of chelating agents, 
modification of inorganic NPs with radionuclides does 
not always require them. For the chelator-based labeling 
the suitability of the chelator agent for the radionuclide 
is essential. Prior the conjugation with the chelator, the 
surface of NPs should be modified with addition of car-
boxyl, thiols and amino groups. After that the further 
radiolabeling process is relatively straightforward. Since 
most of the chelators, such as DOTA, NOTA, BMEDA, 
and so forth are reactive to carboxyl, thiol and amine 
groups, they can be incubated with the modified NPs 
until the conjugation is complete. Afterwards, using the 
same strategy, NPs can be simply shaken with radionu-
clides in an aqueous solution. The main drawback of the 
chelator-based functionalization is that there is no uni-
versal chelating agent suitable for every isotope, which 
means a proper chelator should be selected prior labe-
ling to achieve an efficient modification [232]. However, 
such surface modification changes the pharmacokinet-
ics of NPs, which can reduce the overall effectiveness of 
radionuclide delivery. Another setback of the chelator-
based labeling is the possible detachment of radioisotope, 
which decreases specificity of delivery and therefore 
hampers the potential therapeutic and diagnostic effect 
of a delivery system [233].
Therefore, scientific community is also focused on the 
development of chelator-free labeling approaches. Che-
lator-free radionuclide labeling is subdivided on “hot-
plus-cold” strategy, specific trapping and cation exchange 
(Fig.  10) [234, 235]. In the “hot-plus-cold” labeling 
approach radioactive compound is incorporated into the 
NPs during the synthesis procedure. Such method allows 
to obtain exceptionally stable labeling with high radio-
chemical yields. For example, Zhao et  al. reported the 
64Cu-alloyed AuNPs obtained via “hot-plus-cold” synthe-
sis, showed increased radiolabeling stability [236]. How-
ever, the main drawback of this technique it that it can be 
used only for certain combinations of radionuclide and 
NPs. Additionally, the synthesis should be shorter than 
the half-life of chosen radionuclide in order to preserve 
its functionality [237]. The specific trapping method is 
based on the ability of some metal ions (in case of metal-
lic nuclides) to form stable bonds with oxygen atoms, 
which are usually expressed on the surface of some inor-
ganic NPs. Like for “hot-plus-cold” approach, specific 
trapping requires appropriate combinations of radionu-
clides and NPs. Moreover, for the in vivo applications, the 
stability of formed bond should be previously checked. 
Cation exchange labeling technique replaces an ion in a 
NP by another ion from the solution. This mechanism 
is driven by the relative thermodynamic stability of the 
reactants compared to the products. For this the appro-
priate solvent should be considered. As for other labeling 
methods, a specific combination of NP-cation pairing is 
of great importance for the cation exchange labeling.
As an example of chelator-free radionuclide labeling, 
Chen et  al. developed Si-based delivery systems labeled 
with 89Zr using deprotonated silanol groups inside 
mesopores or on the surface of silica NPs as inherent 
hard oxygen donors for radiolabeling. The resulted sys-
tems demonstrated enhanced stability of 89Zr in mice 
over 3  weeks [238]. Another group showed efficient 
chelator-free labeling of amorphous Si NPs with clini-
cally relevant radioisotopes (89Zr, 68Ga, 111In, 90Y, 177Lu, 
64Cu) by simple adsorption of radionuclides into the 
NP’s surface. In  vivo stability of developed systems was 
demonstrated and the binding stability was found to be 
correlated with the hardness of the radioisotope [239]. 
The same group developed the radiolabeling methods of 
softer isotopes like 64Cu by functionalization of silica NPs 
with thiol groups. The labeling efficiency was improved 
from 74.4% for uncoated silica NPs to 94.5% for sulfur 
coated silica NPs due to the formation of thermodynami-
cally stable bond [240].
Outlooks
The inorganic NPs can possess unique physicochemical 
properties, which can be tuned and optimized by choos-
ing appropriate core material. Therefore, it is possible to 
find an optimal type of NPs, which will provide required 
functionalities of radionuclide delivery systems. In 
other words, apart from radionuclide delivery, NPs with 
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Fig. 10 Schematic illustration of five major strategies for radiolabeling inorganic NPs. a Chelator-mediated complexation, b Specific trapping (b1) 
and ion-exchange (b2). c Hot-plus-cold precursor synthesis, d Proton beam activation. NP: nanoparticle (this figure was reproduced from Goel et al. 
[234] with the required copyright permission)
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magnetic and plasmonic properties make possible simul-
taneous visualization of developed radiopharmaceuticals 
by means of MRI or X-ray imaging. Majority of carbon-
based delivery carriers can be visualized with optical 
fluorescence microscopy, however, to reduce toxic effects 
of these materials an additional surface modification 
is required. Silica-based carriers enables high loading 
capacity due to its porosity and wide functionalization 
possibilities, nevertheless, extra labeling of these carriers 
with, for example, fluorescence moieties make it possible 
optical biodistribution monitoring of such formulations.
The ability to perform chelator-free radiolabeling of 
inorganic NPs allows to achieve more stable incorpora-
tion of radionuclides, which reduces off target effects and 
overall increases amount of delivered cargo.
However, the toxicity of inorganic NPs is still a topic of 
research. Therefore, despite variety of inorganic NPs and 
possibilities of their functionalization, nowadays, they are 
mostly employed in pre-clinical studies with only a few 
types of inorganic NPs are clinically approved (ultrasmall 
Si NPs and  Fe3O4 NPs as contrast agent).
Additionally, inorganic NPs much less effective for tar-
geting of single tumor cells or tumors with lack of vascu-
lature comparing to the mAbs and their fragments. This 
means that NPs cannot be employed for treatment of 
metastatic tumors, due to overall inefficiency [237].
The first steps toward clinical applications of radiola-
beled inorganic NPs have been made in order to under-
stand the biodistribution of these carriers inside the 
human body. There are a number FDA-approved inor-
ganic platforms labeled with radionuclides, which were 
used for medical imaging. Despite the abovementioned 
ultrasmall Si NPs, 99mTc-labeled sulfur and stannous fluo-
ride colloids were reported to be used as imaging agents 
in humans [241]. Therefore, we believe that the clinical 
employment of the inorganic NPs in the radiomedicine 
will seriously increase, due to the multimodal imaging, 
which these particles can offer, as well as fine tuning of 
their physicochemical properties, which helps to predict 
the biological cell response and the possible clinical out-
comes. The recent studies on radionuclide delivery using 
inorganic NPs were presented in Table 3.
Microspheres
Another radionuclide delivery systems that have been 
successfully employed in pre-clinical and clinical stud-
ies are microspheres with size distribution in the range 
of 20–60  µm. Microspheres can be functionalized with 
active ligands to impart them properties of selectivity. 
Nowadays, there are three types of radioactive micro-
spheres approved for clinical use—TheraSpheres (BTG, 
London, UK), SIR-Spheres (Sirtex Medical Limited, 
North Sydney NSW, Australia) and QuiremSpheres 
(Quirem Medical BV, Deventer, the Netherlands) [242].
These microspheres are usually used in radioemboliza-
tion—a procedure, where the microspheres are injected 
via a catheter into the hepatic arteries. The efficiency of 
such microspheres is ensured by the fact that healthy 
hepatic tissue receives its supply mostly from the portal 
vasculature, while the malignant hepatic tumors are fed 
by arterial blood. Thus, administration of large micro-
spheres through the hepatic artery leads to the clogging 
of small tumor capillaries that have a diameter of approx-
imately 8–10 µm. As a result of higher concentration of 
blood vessels in tumor nodules compared to the normal 
tissue, the major amount of spheres becomes lodged 
and emit radiation in the tumor site, leaving the healthy 
parenchyma relatively unaffected [242–245].
All three clinically approved types of microspheres 
share a common mechanism of tumor targeting, each of 
them differs in the means of fabrication, radioactive labe-
ling and choice of materials. These materials possess dif-
ferent physical traits and are applied in slightly different 
medical conditions.
TheraSpheres are insoluble glass beads with 90Y as an 
integral component and with diameter ranging between 
20 and 30 µm. The synthesis of glass microspheres can be 
divided into two main stages: the particle production and 
radionuclide activation. The beads are obtained by melt-
ing at a high temperature a mixture of 89Y oxide (89Y2O3), 
aluminum oxide  (Al2O3) and silicon dioxide  (SiO2). The 
resulting glass is crushed, processed with a flame sprayer 
to even out the particles and passed through sieves to 
pick out particles with required distribution. The sec-
ond stage consists of converting the non-radioactive 89Y 
to 90Y by neutron bombardment in a nuclear reactor. 
The production results in the formation of particles with 
90Y as an integral component [246]. Such method allows 
incorporating relatively high amounts of yttrium. The 
combination of high activity and the particular size dis-
tribution allows to minimize the embolic effect, reducing 
the risk of reflux or stasis/retrograde flow [245, 247, 248].
The SIR-Spheres are microspheres based on biocom-
patible resin with 90Y impregnated on the particle sur-
face. Each bead has a diameter ranging from 20 to 60 µm, 
and specific activity of 50 Bq at calibration. The activity 
of each particle, which is relatively small compared to the 
TheraSphere, is explained by the means of radionuclide 
incorporation: the 90Y is bound exclusively to the resin 
surface in the form of 90Y sulphate.
QuiremSpheres are poly-l-lactic acid based micro-
spheres, containing 165Ho. The size of the particles var-
ies from 15 to 60  µm and the use of poly-l-lactic acid 
allows to achieve the particle density of 1.4 g/cm3, which 
Page 25 of 34Peltek et al. J Nanobiotechnol           (2019) 17:90 
Table 3 Recently studied radionuclide delivery systems based on inorganic NPs
Radionuclide Delivery system Labeling Application Comments Refs.
225Ac Gold coated lanthanide 
phosphate NPs
‘Hot’ + ‘cold’ precursor Radiotherapy McLaughlin et al. developed 
multilayered NPs that can 
deliver multiple a radiations 
and contain the decay daugh-
ters of 225Ac while targeting 
biologically relevant receptors 
in a female BALB/c mouse 
model
[200]
198Au Au NPs ‘Hot’ + ‘cold’ precursor Radiotherapy Katti et al. developed a novel 
approach to treat prostate 
cancer with 198Au NPs, which 
were modified with glucoside 
molecules mangiferin. In vivo 
experiments on severe 
combined immunodeficient 
(SCID) mice revealed over 85% 
reduction of bearing prostate 
tumor volume as compared 
to the control groups
[201]
166Ho Garnet magnetic NPs Neutron activation Radiotherapy Munaweera et al. developed 
magnetic NPs, which were 
modified with 165Ho/cyto-
static drug and navigated into 
tumor area using external 
magnet. In vitro and in vivo 
results suggested that the 
external magnetic field navi-
gation was achieved, since 
higher amounts of 165Ho were 
observed in tumor than in 
liver, which led to the inhibi-
tion of tumor growth
[206]
89Zr Ultrasmall silica NPs Chelation (DFO) PET and optic imaging Chen et al. described synthesis 
of a PEGylated ultrasmall 
silica particles labeled with 
Cy5 dye. Reported NPs were 
modified with chelators and 
anti-HER2 scFv fragments. 
This allowed to achieve more 
efficient tumor-targeting with 
bulk renal clearance, which 
surpasses already existing 
characteristics of scFv mol-
ecules and scFv-conjugated 
NPs larger than 10 nm. The 
experiments in vivo revealed 
a favorable pharmacokinetics 




99mTc Mesoporous silica NPs Reduction of Tc(VII) in  TcO4
− 
using  SnCl2
SPECT Pascual et al. improved target-
ing properties of developed 
Si-based systems by function-
alization of NPs with Mucin 
1 aptamer that is specific to 
breast cancer. Pronounced 
targeted delivery of 99mTc 
into tumor of tumor-bearing 
Balb/c mice was shown and 
monitored with SPECT and 
bioluminescence options
[214]
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is closer to the density of blood (1.06 g/cm3). The 165Ho 
is activated to 165Ho with neutron activation in a nuclear 
reactor. Due to the short half-life period of 165Ho, each 
patient dose of QuiremSpheres needs to be prepared sep-
arately, thus, a specific activity can differ in each dose and 
depends on the needs of a patient [243, 249].
Another difference between yttrium-based micro-
spheres and QuiremSpheres is the biodegradability of the 
latter. While TheraSpheres and SIR-Spheres remain in the 
patient liver as a permanent implant, the QuiremSpheres 
disintegrate leaving only insoluble holmium lactate [250]. 
Such degradation of microspheres positively influences 
the outcome of the treatment and enhances the efficiency 
of consecutive procedures of radioembolization whether 
they would be required in the future.
Choice of radionuclide
The choice of 90Y as a radionuclide for TheraSpheres and 
SIR-Spheres was based on its pure β-emitting proper-
ties with tissue penetration range of 90Y β-radiation of 
2.5  mm (max. 11  mm), which in combination with tar-
geting mechanism majorly restrict irradiation mostly to 
malignant tissues. In addition to that, 90Y has a physical 
half-life suitable for the radiotherapy (64.1 h) and 94% of 
radiation is delivered within 11 days after the drug admis-
sion [251].
The post-procedural visualization of microsphere 
distribution is commonly performed by analyzing the 
bremsstrahlung radiation produced by the decelerating 
β−, but such imaging lacks required precision in dose 
calculation and evaluation. However, the 90Y decay is 
accompanied by positron emission, which is although 
relatively weak (0.003%),  but still can be detected with 
highly sensitive enough tomographs, thus, making PET 
possible with specific equipment (Fig. 11) [252].
Although 90Y-based microspheres have proved to be 
overall effective for hepatic tumor treatment, two major 
drawbacks lead to the development of 166Ho micro-
spheres. Firstly, in order to achieve a therapeutic amount 
of 90Y, long neutron activation times (more than 2 weeks) 
are required. Secondly, it was proved difficult to track the 
biodistribution of yttrium microspheres, due to the fact 
90Y being an almost pure β− emitter [254].
166Ho emits low energy γ rays, which accompany 
electron radiation, when it reaches its steady state as 
Table 3 (continued)
Radionuclide Delivery system Labeling Application Comments Refs.
89Zr Mesoporous silica NPs Chelation with the deproto-
nated silanol groups
Photodynamic therapy Kamkaew et al. reported 
mesoporous silica NPs loaded 
with 89Zr and photosensi-
tizer Chlorin e6, which can 
be activated by Cherenkov 
radiation from 89Zr. Therefore, 
the developed radionuclide 
delivery systems overcame 
the limitations of conven-
tional photodynamic therapy, 
which requires light source to 
activate photosensitizer
[216]
225Ac CNT Chelation (DOTA) Radiotherapy Ruggiero et al. developed CNT-
based carriers to deliver 225Ac 
into the tumor angiogenic 
vessels, which express the 
monomeric vascular endothe-
lial-cadherin. The developed 
carrier system was able to 
achieve 100-fold amplified 
cargo delivery (relative to the 
gold standard for targeted 
therapy—IgG)
[223]
131I Reduced graphene oxide Standard chloramine-T oxida-
tion method
Photothermal and radiotherapy Chen et al. developed radio-
labeled graphene-derivative, 
which offers the ability of 
in vivo tumor imaging, and 
is able to deliver both pho-
tothermal and radiotherapy 
at the same time in order to 
achieve synergistic thera-
peutic effect using a single 
nanoscale theranostic agent
[226]
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daughter product 166Er. This makes possible the visu-
alization of microsphere distribution by SPECT/CT. In 
addition, both holmium and its decay product erbium 
are lanthanides, which makes possible the visualization 
of microsphere by the means MRI of the paramagnetic 
metal [255].
Outlooks
Microspheres have already been successfully imple-
mented in clinical practice long time ago and the recent 
developments of QuiremSpheres shows that the scien-
tific community is currently developing new approaches 
in microspheres employment as radionuclide carriers. 
However, it is important to mention that implementa-
tion of microspheres is strictly limited to the radioembo-
lization procedure, which heavily relies on the peculiar 
blood supply of liver cancer, and, therefore, cannot be 
used for the treatment of other oncological diseases. Fur-
ther improvements of the microspheres can be focused 
around the enhancement of microsphere visualization, 
which would allow more precise estimation of the deliv-
ered radiation dose. In addition, modifications of sphere 
composition can be made in order to ensure the micro-
sphere degradation and subsequent excretion.
Conclusion and future prospects
The radionuclides and their capacity to emit ionizing 
radiation have been employed in clinical practice not 
only for diagnostic, but also for therapy, with relevant 
contribution in the several fields of medicine. Given the 
nature of radioisotopes, as well as the desired goal (e.g. 
biochemical pathway investigation of radionuclide, bio-
imaging and anomaly detection, curative or palliative 
treatment or for theranostic purpose), an appropriate 
carrier platform should be attentively evaluated and sug-
gested. Due to the advances in chemistry and cellular 
biology, many radionuclide delivery systems have been 
developed and demonstrated its efficiency compared to 
individual alternatives in vitro and in vivo. In this review 
article, we consider the most trendy radionuclide delivery 
systems, which can be categorized into four groups: (i) 
antibodies and their fragments, (ii) organic and (iii) inor-
ganic nanoparticles, and (iv) microspheres. The transla-
tion of most of them into clinics has not progressed as 
rapidly as expected, since each of these platforms possess 
advantages and disadvantages.
Antibody-based delivery systems are widely employed 
in therapy and diagnostics due to their distinct pharma-
cokinetics: highly specific binding to the antigens, easy 
clearance because of relatively small size. The use of 
intact antibodies is restricted by poor penetration into 
solid tumors, whereas the immune system undergoes Fc-
mediated bystander activation. However, this limitation 
can be overcome with antibody fragments. Nevertheless, 
due to the ultrasmall size of antibody fragments it is not 
always possible to perform effective labeling with radio-
metals, since pharmacokinetics of antibodies are affected 
by incorporating of chelators.
The use of NPs as radionuclide delivery platforms is 
rapidly developing field due to their unique physico-
chemical and biological characteristics. To date, many 
efforts are focused on the translation of developed radi-
opharmaceuticals based on NPs into clinical practice. 
However, their fully introduction in clinics is postponed 
due to technical and biological limitations. There is 
need for the development of more facile procedures for 
the surface modification and radiolabeling of NPs. At 
Fig. 11 Superselective segmental radioembolization. a CT scan before treatment showing multinodular tumor. b PET scan showing intense 
radiation after administration of 90Y resin microspheres. c Significant atrophy of liver segment and lack of tumor activity 1 year after treatment (this 
figure is reproduced from Sangro et al. [253] with required copyright permission)
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the same time, biological barriers can induce the differ-
ent response to the same nanomaterials from patient to 
patient. The additional stabilization of NPs are highly 
required, since after the first contact of NPs with the 
biological fluids organic compounds tend to bind to the 
NPs surface forming so-called “corona” around the par-
ticles. This corona can induce NPs aggregation and sig-
nificantly change pharmacokinetic profile of NP-based 
radiopharmaceuticals.
Compared to the inorganic NPs, there are some exam-
ple of successful clinical trials of organic NPs, espe-
cially liposomes  ([64Cu]MM-302 and 188Re-BMEDA 
liposomes). The clinical implementation of inorganic NPs 
is limited by concerns over their toxicity, non-optimal 
utilization and in  vivo behavior. As an advantage, inor-
ganic NPs provide additional possibilities of multimodal 
imaging, for examples, magnetic NPs as contrast agent 
for MRI, Au NPs as contrast agent for X-ray imaging, 
C-based NPs as contrast agent for fluorescence imag-
ing. Inorganic and organic NPs enable high radionuclides 
payloads, flexibility of radiolabeling options and con-
trolled physicochemical parameters (size, shape, chemi-
cal composition, stiffness), what results in increased 
amount of delivered radionuclides in the site of interest 
and improved tissue penetration and, thus, the efficiency 
of radiotherapy.
It seems that the scientific community is now at the 
stage of the developing the advanced hybrid radionuclide 
carriers with complex architecture taking advantages 
from each individual delivery system. The integration 
of various organic and inorganic NPs (e.g. liposomes, 
micelles, metal NPs, polymer conjugates etc.) in sin-
gle smart platform allows to achieve multifunctionality 
and enable multimodal imaging. It also leads to further 
increase the loading capacity, enhance the biomembrane-
crossing rate, and the tissue-penetration efficiency. At the 
same time, the functionalization of this hybrid platform 
with targeting moieties may enable the increased target-
ing delivery of radionuclides.
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